What question did this study set out to answer?

To evaluate and compare the clearance and anticoagulant pharmacokinetics of standard heparin versus a low molecular weight heparin (PK 10169) following single intravenous administration in patients with chronic renal failure.

April 21, 2009Haemostasis

Pharmacokinetic Studies of Standard Heparin and Low Molecular Weight Heparin in Patients with Chronic Renal Failure

View Full Paper

Ask AI

Bookmark

Why the study?

Does the pharmacokinetic profile of single intravenous injection of LMW heparin differ from standard heparin in patients with chronic renal failure?

Population

Patients with chronic renal failure

Comparison

Low molecular weight heparin administered as a… vs Standard commercial heparin administered as a…

Design

Other

Authors

GFGilles FolléaInserm MLMartine LavilleUniversité Claude Bernard Lyon 1 NPN PozetUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

May support LMW heparin preference in chronic renal failure; hypothesis-generating pending larger trials.

Key Points

To evaluate and compare the clearance and anticoagulant pharmacokinetics of standard heparin versus a low molecular weight heparin (PK 10169) following single intravenous administration in patients with chronic renal failure.
Administered single intravenous injections of standard commercial heparin and low molecular weight heparin (PK 10169) to patients with chronic renal failure.
Measured anticoagulant disappearance profiles using activated partial thromboplastin time (APTT) along with chromogenic anti-Xa and anti-IIa assays.
Standard heparin displayed an initial rapid decay followed by a convex disappearance curve, indicating a predominant saturable elimination mechanism in renal failure.
Low molecular weight heparin anti-Xa activity demonstrated linear or concave elimination curves with a longer apparent half-life, demonstrating non-saturable clearance and minimal dependence on renal elimination.

Structured PICO

Does the pharmacokinetic profile of single intravenous injection of LMW heparin differ from standard heparin in patients with chronic renal failure?

Population

Patients with chronic renal failure

Intervention

Low molecular weight (LMW) heparin (PK 10169) administered as a single intravenous injection

Comparator

Standard commercial heparin administered as a single intravenous injection

Outcome

Disappearance of anticoagulant activities (pharmacokinetics) measured by activated partial thromboplastin time (APTT) and chromogenic assays of anti-Xa and anti-IIa activitiessurrogate

LMW heparin elimination appears to be non-saturable and minimally dependent on renal function compared to standard heparin in patients with chronic renal failure.

Cite This Study

Folléa et al. (2009) studied this question.

synapsesocial.com/papers/6a6fecfbfebe604dd708bf39 https://doi.org/10.1159/000215284

View Full Paper

Ask AI

Bookmark

Pharmacokinetic Studies of Standard Heparin and Low Molecular Weight Heparin in Patients with Chronic Renal Failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Pharmacokinetic Studies of Standard Heparin and Low Molecular Weight Heparin in Patients with Chronic Renal Failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider